ArticleJournal of advanced research2026
Selectively targeting UDP-glucose 4-epimerase MoUGE1 for controlling rice blast disease.
Article in Journal of advanced research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- The MoSR-MoDde1 Regulatory Axis: A Novel Determinant of DMI Sensitivity and a Target for Sustainable Rice Blast Control.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- MoSun4 Contributes to Pathogenicity and Is Associated with Altered Expression of Virulence-Related Genes inJournal of fungi (Basel, Switzerland) · 2026Article
- Enhanced Biocontrol of Root-Knot Nematodes Through Co-Cultivation ofJournal of fungi (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThe fungal cell wall, a dynamic structure critical for pathogenesis, is composed of polysaccharides and proteins. UDP-glucose 4-epimerases (UGEs) play a pivotal role in cell wall synthesis by converting UDP-galactose between UDP-glucose. This study investigates the role of MoUGE1 in Magnaporthe oryzae pathogenesis and explores its potential as an antifungal target for fungal disease control. A lead inhibitor targeting MoUGE1 was identified through virtual screening.
objectivesThe aims of this study were to elucidate the role of MoUGE1 in M. oryzae during rice blast pathogenesis, assess its potential as an antifungal target, and identify potential MoUGE1 inhibitors through virtual screening to control rice blast.
methodsTo analyses the role of MoUGE1 in M. oryzae, we generated Δuge1 mutants via split-PCR-mediated gene knockout. The impact of MoUGE1 on fungal growth, cell wall composition, and plant infection was assessed. Metabolomic analysis revealed the impact of MoUGE1 deletion on metabolic processes of rice blast. Structure-based virtual screening, molecular dynamics (MD) simulation and surface plasmon resonance (SPR) used to find hit compounds inhibiting MoUGE1.
resultsThe Δuge1 exhibited reduced mycelial growth, altered cell wall and cell membrane composition, and impaired plant infection. Metabolomic analysis and western blot revealed accumulation in UDP-galactose and alteration of N-glycosylation, leading to cell wall instability and increased sensitivity to cell wall stressors. Virtual screening identified lig122132 as a potential MoUGE1 inhibitor, which was further confirmed through MD simulation and SPR, showing stable binding to the MoUGE1.
conclusionOur findings emphasize the significance of MoUGE1 in fungal cell wall integrity, appressorium function, and virulence in M. oryzae. Identifying MoUGE1 as a target for antifungal intervention provides new insights into the molecular mechanisms of rice blast pathogenesis and paves the way for developing innovative strategies against this major agricultural disease. The potential MoUGE1 inhibitor, lig122132, is a promising starting point for the development of novel fungicides to control rice blast.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.